- Home
- MLTX
as 07-26-2024 4:00pm EST
MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. The company derives maximum revenue from United Kingdoms.
| Founded: | 2021 | Country: | Switzerland |
| Employees: | N/A | City: | ZUG |
| Market Cap: | 2.7B | IPO Year: | N/A |
| Target Price: | $76.33 | AVG Volume (30 days): | 421.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $35.11 - $64.98 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of MoonLake Immunotherapeutics (MLTX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Santos da Silva Jorge | MLTX | Chief Executive Officer | Feb 27 '24 | Sell | $55.00 | 62,810 | $3,454,550.00 | 3,043,619 | SEC Form 4 |
| Santos da Silva Jorge | MLTX | Chief Executive Officer | Feb 27 '24 | Sell | $55.00 | 56,065 | $3,083,575.00 | 2,987,554 | SEC Form 4 |
| Santos da Silva Jorge | MLTX | Chief Executive Officer | Feb 27 '24 | Sell | $55.89 | 4,740 | $264,918.60 | 2,982,814 | SEC Form 4 |
| Reich Kristian | MLTX | Chief Scientific Officer | Feb 27 '24 | Sell | $55.00 | 29,491 | $1,622,005.00 | 2,957,483 | SEC Form 4 |
| Reich Kristian | MLTX | Chief Scientific Officer | Feb 27 '24 | Sell | $55.00 | 29,431 | $1,618,705.00 | 70,071 | SEC Form 4 |
| Reich Kristian | MLTX | Chief Scientific Officer | Feb 27 '24 | Sell | $55.00 | 31,910 | $1,755,050.00 | 2,925,573 | SEC Form 4 |
| Reich Kristian | MLTX | Chief Scientific Officer | Feb 27 '24 | Sell | $55.00 | 28,090 | $1,544,950.00 | 41,981 | SEC Form 4 |
| Santos da Silva Jorge | MLTX | Chief Executive Officer | Feb 21 '24 | Sell | $55.27 | 1,125 | $62,178.75 | 3,106,429 | SEC Form 4 |
| Reich Kristian | MLTX | Chief Scientific Officer | Feb 20 '24 | Sell | $57.45 | 10,000 | $574,500.00 | 2,987,483 | SEC Form 4 |
| Reich Kristian | MLTX | Chief Scientific Officer | Feb 20 '24 | Sell | $57.43 | 10,000 | $574,300.00 | 100,071 | SEC Form 4 |
| Reich Kristian | MLTX | Chief Scientific Officer | Feb 20 '24 | Sell | $55.31 | 509 | $28,152.79 | 2,986,974 | SEC Form 4 |
| Reich Kristian | MLTX | Chief Scientific Officer | Feb 20 '24 | Sell | $55.30 | 569 | $31,465.70 | 99,502 | SEC Form 4 |
| Santos da Silva Jorge | MLTX | Chief Executive Officer | Feb 15 '24 | Sell | $60.18 | 20,000 | $1,203,600.00 | 3,147,554 | SEC Form 4 |
| Santos da Silva Jorge | MLTX | Chief Executive Officer | Feb 15 '24 | Sell | $60.15 | 20,000 | $1,203,000.00 | 3,127,554 | SEC Form 4 |
| Santos da Silva Jorge | MLTX | Chief Executive Officer | Feb 15 '24 | Sell | $57.44 | 20,000 | $1,148,800.00 | 3,107,554 | SEC Form 4 |
| Reich Kristian | MLTX | Chief Scientific Officer | Feb 14 '24 | Sell | $62.42 | 10,000 | $624,200.00 | 3,017,483 | SEC Form 4 |
| Reich Kristian | MLTX | Chief Scientific Officer | Feb 14 '24 | Sell | $62.43 | 10,000 | $624,300.00 | 130,071 | SEC Form 4 |
| Reich Kristian | MLTX | Chief Scientific Officer | Feb 14 '24 | Sell | $60.17 | 10,000 | $601,700.00 | 3,007,483 | SEC Form 4 |
| Reich Kristian | MLTX | Chief Scientific Officer | Feb 14 '24 | Sell | $60.16 | 10,000 | $601,600.00 | 120,071 | SEC Form 4 |
| Reich Kristian | MLTX | Chief Scientific Officer | Feb 14 '24 | Sell | $60.15 | 10,000 | $601,500.00 | 2,997,483 | SEC Form 4 |
| Reich Kristian | MLTX | Chief Scientific Officer | Feb 14 '24 | Sell | $60.15 | 10,000 | $601,500.00 | 110,071 | SEC Form 4 |
| Bodenstedt Matthias | MLTX | Chief Financial Officer | Dec 19 '23 | Sell | $59.22 | 94,736 | $5,610,265.92 | 526,167 | SEC Form 4 |
| Bodenstedt Matthias | MLTX | Chief Financial Officer | Dec 19 '23 | Sell | $58.34 | 5,264 | $307,101.76 | 520,903 | SEC Form 4 |
Latest MoonLake Immunotherapeutics News
MLTX Breaking Stock News: Dive into MLTX Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Oppenheimer Initiates MoonLake Immunotherapeutics at Outperform With $104 Price Target
GlobeNewswire
2 months ago
$6.6 Billion Digital X-ray Market, 2024-2029: Development of AI-based Digital X-Ray Systems Present Business Opportunities
Motley Fool
2 months ago
2 Reasons to Buy Rivian Stock (and 1 Big Reason to Sell)
CNW Group
2 months ago
DFR Gold Inc. Announces Amendment of WUO Land Option and Insider Loans
Investor's Business Daily
2 months ago
Walmart Stock Climbs After Dow Jones Giant Receives Upgrade, Major Price Target Hike
CNW Group
2 months ago
EPCOR and HAWSCo Enter Ownership Transfer Agreement
GlobeNewswire
2 months ago
Video on Demand (VoD) Market Report 2024-2034: Netflix, Amazon, Google and Hulu Dominate
Yahoo Finance Video
2 months ago
Southwest Airlines stock pops on report of Elliott's $2B stake
Compare MLTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MLTX MoonLake Immunotherapeutics - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.